950 related articles for article (PubMed ID: 27365197)
1. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
[TBL] [Abstract][Full Text] [Related]
2. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
3. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
5. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
[TBL] [Abstract][Full Text] [Related]
6. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
7. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
[TBL] [Abstract][Full Text] [Related]
8. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma.
Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M
Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021
[TBL] [Abstract][Full Text] [Related]
9. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
11. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
Coates AS; Winer EP; Goldhirsch A; Gelber RD; Gnant M; Piccart-Gebhart M; Thürlimann B; Senn HJ;
Ann Oncol; 2015 Aug; 26(8):1533-46. PubMed ID: 25939896
[TBL] [Abstract][Full Text] [Related]
12. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
13. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients.
Omarini C; Guaitoli G; Noventa S; Andreotti A; Gambini A; Palma E; Papi S; Tazzioli G; Balduzzi S; Dominici M; Cascinu S; Piacentini F
Eur J Surg Oncol; 2017 Apr; 43(4):613-618. PubMed ID: 27793416
[TBL] [Abstract][Full Text] [Related]
14. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
[TBL] [Abstract][Full Text] [Related]
15. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
16. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
[TBL] [Abstract][Full Text] [Related]
17. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
19. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration.
Yu Y; Cui N; Li HY; Wu YM; Xu L; Fang M; Sheng Y
BMC Cancer; 2016 Oct; 16(1):808. PubMed ID: 27756234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]